Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avigen initiates opioid withdrawal trial
The study is largely funded by the National Institute on Drug Abuse and will be run jointly by the New York State Psychiatric Institute and Columbia University. The
The study is largely funded by the National Institute on Drug Abuse and will be run jointly by the New York State Psychiatric Institute and Columbia University. The
The Phase IIa multi-center, open-label study enrolled 32 subjects and was conducted at 12 US sites. Study patients received 6R-BH4 at 2.5mg/kg, 5mg/kg, 10mg/kg and 20mg/kg for four
The project is sponsored by Simdat – a program funded by the European Commission under the Information Society Technologies Programme designed to test and enhance Grid data technology
Under the terms of the agreement, Miraculins will issue to Mount Sinai Hospital (MSH) 310,000 common shares from treasury, subject to a standard four-month and one day resale
Accell Evo3 is said to be the latest generation in demineralized bone matrix and is composed of an optimized blend of particulate demineralized bone matrix (DBM), the proprietary
Mr Hobbs is president and CEO of AngioDynamics, a medical device company specializing in the development and sales of medical technology serving the needs of interventional oncologists and
The milestone was triggered by Progenics’s initiation of a Phase I clinical trial with its prostate-specific membrane antigen (PSMA)-targeted antibody-drug conjugate (ADC) for patients with hormone-refractory prostate cancer.
A separate efficacy supplement that included data from patients with cutaneous T-cell lymphoma (CTCL) whose malignant cells did not test positive for the CD25 component of the IL-2
This double-blind, placebo-controlled Phase I study (Study 290-001), is expected to enroll up to 60 adult healthy volunteers. MGCD290 will be administered orally at an initial starting dose
Lorus has also announced that Central America has been added to the territories covered in the exclusive licensing agreement with Zor Pharmaceuticals. Due to the extension of the